# Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

> **NCT01007448** · PHASE4 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Refractory Cutaneous T-cell Lymphoma

## Interventions

- **DRUG:** Bexarotene

## Key facts

- **NCT ID:** NCT01007448
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-06
- **Primary completion:** 2014-02-20
- **Final completion:** 2014-02-20
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01007448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01007448, "Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01007448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*